Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $11.71

Key Points

• Humacyte, Inc. has been given a consensus rating of "Buy" by analysts, with six out of eight firms recommending a buy and an average twelve-month price target of $11.71.
• Institutional investors hold 44.71% of the company's stock, with several institutions recently purchasing new stakes valued between $27,000 and $37,000.
• The company's stock opened at $2.40 and has a 52-week range of $1.15 to $9.79, indicating significant volatility.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.71.

Several research analysts have recently commented on HUMA shares. Benchmark reduced their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. HC Wainwright initiated coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target on the stock. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Wednesday, July 23rd.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. Northern Trust Corp grew its position in shares of Humacyte by 11.5% during the fourth quarter. Northern Trust Corp now owns 901,194 shares of the company's stock worth $4,551,000 after buying an additional 92,708 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Humacyte during the fourth quarter worth about $99,000. CenterBook Partners LP acquired a new position in shares of Humacyte during the fourth quarter worth about $6,463,000. Finally, Geode Capital Management LLC grew its position in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after buying an additional 94,915 shares in the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Price Performance

Humacyte stock traded down $0.12 during trading on Friday, reaching $2.28. The company had a trading volume of 5,792,632 shares, compared to its average volume of 4,153,934. The firm's 50-day simple moving average is $2.43 and its 200 day simple moving average is $2.65. Humacyte has a 1-year low of $1.15 and a 1-year high of $8.72. The firm has a market capitalization of $353.67 million, a PE ratio of -3.30 and a beta of 1.90. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. As a group, equities research analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.